Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting From Highly Emetogenic Chemotherapy: a Randomized, Multicenter, Double-blind, Placebo-controlled Phase III Trial

NCT02203253 is registered in ClinicalTrials.gov with China Medical University, China as lead sponsor.

NCT NCT02203253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02203253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting From Highly Emetogenic Chemotherapy: a Randomized, Multicenter, Double-blind, Placebo-controlled Phase III Trial
Lead sponsor
China Medical University, China
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2014
Completion date
August 31, 2016
Enrollment
642 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms